{
  "ticker": "IMVT",
  "company_name": "Immunovant, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT07188844",
      "title": "An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)",
      "status": "ENROLLING_BY_INVITATION",
      "phase": "PHASE2",
      "condition": "Chronic Inflammatory Demyelinating Polyneuropathy",
      "start_date": "2025-08-28",
      "completion_date": "2028-11",
      "enrollment": 0,
      "sponsor": "Immunovant Sciences GmbH"
    },
    {
      "nct_id": "NCT07018323",
      "title": "A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease",
      "status": "RECRUITING",
      "phase": "PHASE2",
      "condition": "Graves' Disease",
      "start_date": "2025-06-19",
      "completion_date": "2027-05",
      "enrollment": 0,
      "sponsor": "Immunovant Sciences GmbH"
    },
    {
      "nct_id": "NCT05403541",
      "title": "Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "condition": "Generalized Myasthenia Gravis",
      "start_date": "2022-06-27",
      "completion_date": "2025-04",
      "enrollment": 0,
      "sponsor": "Immunovant Sciences GmbH"
    },
    {
      "nct_id": "NCT05907668",
      "title": "A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "condition": "Graves Disease",
      "start_date": "2023-05-15",
      "completion_date": "2025-07",
      "enrollment": 0,
      "sponsor": "Immunovant Sciences GmbH"
    },
    {
      "nct_id": "NCT06727604",
      "title": "A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease",
      "status": "RECRUITING",
      "phase": "PHASE2",
      "condition": "Graves' Disease",
      "start_date": "2024-12-17",
      "completion_date": "2028-06",
      "enrollment": 0,
      "sponsor": "Immunovant Sciences GmbH"
    },
    {
      "nct_id": "NCT06754462",
      "title": "A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "condition": "Rheumatoid Arthritis",
      "start_date": "2025-01-10",
      "completion_date": "2027-09",
      "enrollment": 0,
      "sponsor": "Immunovant Sciences GmbH"
    },
    {
      "nct_id": "NCT03938545",
      "title": "ASCEND GO-2: Study of RVT-1401 for the Treatment of Participants With Active, Moderate to Severe Graves' Ophthalmopathy ( GO )",
      "status": "TERMINATED",
      "phase": "PHASE2",
      "condition": "Graves' Ophthalmopathy (GO)",
      "start_date": "2019-07-23",
      "completion_date": "2021-04-15",
      "enrollment": 0,
      "sponsor": "Immunovant Sciences GmbH"
    },
    {
      "nct_id": "NCT05581199",
      "title": "To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "condition": "Chronic Inflammatory Demyelinating Polyneuropathy",
      "start_date": "2022-12-15",
      "completion_date": "2027-01",
      "enrollment": 0,
      "sponsor": "Immunovant Sciences GmbH"
    },
    {
      "nct_id": "NCT06979531",
      "title": "Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity",
      "status": "RECRUITING",
      "phase": "PHASE2",
      "condition": "Primary Sj\u00f6gren's Syndrome",
      "start_date": "2025-06-30",
      "completion_date": "2028-07",
      "enrollment": 0,
      "sponsor": "Immunovant Sciences GmbH"
    },
    {
      "nct_id": "NCT07032662",
      "title": "IMVT-1402 in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)",
      "status": "RECRUITING",
      "phase": "PHASE2",
      "condition": "Chronic Inflammatory Demyelinating Polyneuropathy",
      "start_date": "2025-03-18",
      "completion_date": "2030-05",
      "enrollment": 0,
      "sponsor": "Immunovant Sciences GmbH"
    }
  ],
  "summary": {
    "total_trials": 19,
    "by_phase": {
      "PHASE2": 14,
      "PHASE3": 5
    },
    "by_status": {
      "ENROLLING_BY_INVITATION": 1,
      "RECRUITING": 7,
      "ACTIVE_NOT_RECRUITING": 5,
      "TERMINATED": 2,
      "NOT_YET_RECRUITING": 1,
      "COMPLETED": 3
    },
    "active_trials": 13,
    "completed_trials": 3,
    "conditions": [
      "Chronic Inflammatory Demyelinating Polyneuropathy",
      "Generalized Myasthenia Gravis",
      "Graves Disease",
      "Graves' Disease",
      "Graves' Ophthalmopathy",
      "Graves' Ophthalmopathy (GO)",
      "Myasthenia Gravis",
      "Primary Sj\u00f6gren's Syndrome",
      "Rheumatoid Arthritis",
      "Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus",
      "Thyroid Eye Disease",
      "Warm Autoimmune Hemolytic Anemia"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:19:02.757432",
    "search_query": "Immunovant, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Immunovant,+Inc."
  }
}